Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipases A2
Open accessThe DOI matches its Crossref record.
Abstract
&NA; A need exists to develop specific and clinically useful inhibitors of toxic enzymes present in snake venoms, responsible for severe tissue damage and life‐threatening effects occurring in thousands of people suffering envenomations globally. LY315920 (Varespladib, S‐5920, A‐001), a low molecular weight drug developed to inhibit several human secreted phospholipases A2 (PLA2s), was recently shown to also inhibit PLA2s in whole snake venoms with high potency, yet no studies have examined its direct effect on purified snake venom PLA2s. This work evaluated the ability of LY315920 to neutralize the enzymatic and toxic activities of three isolated PLA2 toxins of structural groups I (pseudexin) and II (crotoxin B and myotoxin I), and their corresponding whole venoms. In vitro, LY315920 inhibited the catalytic activity of these three enzymes upon a synthetic substrate. The drug also blocked their cytotoxic effect on cultured murine myotubes. In mice, preincubation of the toxins or venoms with LY315920, followed by their intramuscular injection, resulted in significant inhibition of muscle damage. Finally, immediate, independent injection of LY315920 at the site of toxin or venom inoculation also resulted in a large reduction of myonecrosis in the case of pseudexin and myotoxin‐I, and of Pseudechis colletti and Bothrops asper whole venoms, suggesting a possible method of drug delivery in emergency situations. Present findings add evidence to suggest the possibility of using LY315920 as a field antidote in snakebites, aiming to limit the myonecrosis induced by many venom PLA2s in the clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bittenbinder, M. A., van Thiel, J., Cardoso, F. C., Casewell, N. R., Gutiérrez, J.-M., Kool, J., & Vonk, F. J. (2024) · Communications Biology · doi:10.1038/s42003-024-06019-6 · Cited by 132
Self-citationGutiérrez, J. M., Lewin, M. R., Williams, D. J., & Lomonte, B. (2020) · Toxins · doi:10.3390/toxins12020131 · Cited by 92
“Furthermore, Varespladib was effective in the inhibition of myotoxicity induced by crude venoms and isolated PLA2s of viperid and elapid species [20,21].”
BackgroundSelf-citationHall, S. R., Rasmussen, S. A., Crittenden, E., Dawson, C. A., Bartlett, K. E., Westhorpe, A. P., Albulescu, L.-O., Kool, J., Gutiérrez, J. M., & Casewell, N. R. (2023) · Nature Communications · doi:10.1038/s41467-023-43510-w · Cited by 63
“Unexpectedly, the PLA 2 inhibitor varespladibwasineffective againstany of thevenoms tested, despiteit displaying impressive results against systemic venom-induced toxicity previously 29,34,46 – 49 .”
Self-citationXie, C., Albulescu, L.-O., Still, K. B. M., Slagboom, J., Zhao, Y., Jiang, Z., Somsen, G. W., Vonk, F. J., Casewell, N. R., & Kool, J. (2020) · Biomedicines · doi:10.3390/biomedicines8060165 · Cited by 58
Carter, R. W., Gerardo, C. J., Samuel, S. P., Kumar, S., Kotehal, S. D., Mukherjee, P. P., Shirazi, F. M., Akpunonu, P. D., Bammigatti, C., Bhalla, A., et al. (2022) · Toxins · doi:10.3390/toxins15010022 · Cited by 39
Self-citation
Metadata
- Authors
- Bryan-Quirós, W., Fernández, J., Gutiérrez, J. M., Lewin, M. R., & Lomonte, B.
- Venue
- Toxicon
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 157
- Pages
- 1-7
- ISSN
- 0041-0101 (ISSN-L)
- OpenAlex
- W2900543198
- Cited by
- 67
- References
- 0
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipases A2. https://app.cochat.ai/papers/10.1016/j.toxicon.2018.11.292
- The paper
- Bryan-Quirós, W., Fernández, J., Gutiérrez, J. M., Lewin, M. R., & Lomonte, B. (2019). Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipases A2. Toxicon. https://doi.org/10.1016/j.toxicon.2018.11.292
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.